Drugs & Medical Devices
Get ready for the next wave of pharmaceutical litigation with HarrisMartin's Drugs & Medical Devices. This reporter will keep you one step ahead of drug and medical device litigation with in-depth investigations, guest commentaries and objective courtroom coverage on today's and tomorrow's hottest drugs and supplements.
SEARCH THE ARCHIVES
Issue #151, June 2020
A New Jersey federal judge has refused to dismiss a multi-plaintiff action accusing Johnson & Johnson Consumer Inc. of misrepresenting that its Tylenol Extra Strength Rapid Release Gelcaps relieve pain “even faster than before,” when in fact they work slower than acetaminophen.
The Judicial Panel on Multidistrict Litigation has been asked to create a federal docket for cases involving hip devices consisting of a Profemur total hip implant modular femoral neck coupled with a modular titanium Profemur femoral stem.
A California federal judge has awarded Otsuka America Pharmaceutical Inc. summary judgment in an Abilify action, ruling that the plaintiff failed to show that the antipsychotic drug caused her to develop an involuntary movement disorder.
The Food and Drug Administration has issued a warning letter to Allergan Inc., accusing it of failing to conduct post-approval studies for its silicone gel-filled implants as required by premarket approval orders.
A Montana federal judge has ordered Wright Medical Technology Inc. to produce in a Profemur hip implant case a list of previous lawsuits involving a fracture of the same component that allegedly failed in the instant action.
An Ohio federal judge has awarded Medtronic Inc. summary judgment in a lawsuit targeting its SynchroMed II Infusion System, finding the claims are time-barred because the plaintiff knew the device could have caused her injuries more than two years before filing suit.
Issue #150, May 2020
A Massachusetts federal judge has allowed negligent failure-to-warn claim to proceed against American Medical Systems in a pelvic mesh case, finding the plaintiff has presented sufficient evidence that the manufacturer did not adequately warn of certain risks.
The judge overseeing the Zantac multidistrict litigation docket has appointed as lead counsel Tracy Finken of Anapol Weiss, Robert Gilbert of Kopelowitz Ostrow Ferguson Weiselberg Gilbert, Michael McGlamry of Pope McGlamry and Adam Pulaski of Pulaski Kherkher.
A California appellate court has reinstated the eligibility of thousands of Risperdal and Invega gynecomastia cases, finding the failure-to-warn claims are not preempted because there is clear evidence that the FDA would have allowed Janssen Pharmaceuticals Inc. to change the drug’s label via the Changes Being Effected process.
A Texas federal judge has dismissed a lawsuit alleging a link between certain popular antibiotics and a penis condition known as Peyronie’s disease, ruling that the plaintiff failed to overcome the presumption of no liability for labels approved by the Food and Drug Administration.